Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia.

Washida K, Takeda T, Habara T, Sato S, Oka T, Tanaka M, Yoshimura Y, Aoki S.

Neuropsychiatr Dis Treat. 2013;9:861-8. doi: 10.2147/NDT.S45697. Epub 2013 Jun 19.

2.

The history of childhood trauma among individuals with ultra high risk for psychosis is as common as among patients with first-episode schizophrenia.

Sahin S, Yüksel Ç, Güler J, Karadayı G, Akturan E, Göde E, Özhan AA, Üçok A.

Early Interv Psychiatry. 2013 Nov;7(4):414-20. doi: 10.1111/eip.12022. Epub 2013 Jan 24.

PMID:
23343404
3.

Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.

Bervoets C, Morrens M, Vansteelandt K, Kok F, de Patoul A, Halkin V, Pitsi D, Constant E, Peuskens J, Sabbe B.

CNS Drugs. 2012 Nov;26(11):975-82. doi: 10.1007/s40263-012-0003-4. Erratum in: CNS Drugs. 2012 Nov;26(11):1011-2.

PMID:
23018547
4.

[Minor neurological and physical anomalies in patients with first-episode psychosis].

Mhalla A, Boussaïd N, Gassab L, Gaha L, Mechri A.

Encephale. 2013 Jun;39(3):149-54. doi: 10.1016/j.encep.2012.06.030. Epub 2012 Oct 12. French.

PMID:
23095597
5.

Association between impaired brain activity and volume at the sub-region of Broca's area in ultra-high risk and first-episode schizophrenia: A multi-modal neuroimaging study.

Iwashiro N, Koike S, Satomura Y, Suga M, Nagai T, Natsubori T, Tada M, Gonoi W, Takizawa R, Kunimatsu A, Yamasue H, Kasai K.

Schizophr Res. 2016 Apr;172(1-3):9-15. doi: 10.1016/j.schres.2016.02.005. Epub 2016 Feb 9.

PMID:
26873807
6.

[Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].

Bartkó G, Trixler M, Bitter I, Degrell I, Füredi J, Faludi G; Ziprasidonra Váltást Vizsgáló Munkacsoport.

Neuropsychopharmacol Hung. 2006 Dec;8(4):201-9. Hungarian.

PMID:
17211055
7.

Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).

Miyaoka T, Furuya M, Horiguchi J, Wake R, Hashioka S, Tohyama M, Mori N, Minabe Y, Iyo M, Ueno S, Ezoe S, Murotani K, Hoshino S, Seno H.

Psychopharmacology (Berl). 2015 Jan;232(1):155-64. doi: 10.1007/s00213-014-3645-8. Epub 2014 Jun 13.

PMID:
24923986
8.

Neurocognitive impairments in individuals at ultra-high risk for psychosis: Who will really convert?

Bang M, Kim KR, Song YY, Baek S, Lee E, An SK.

Aust N Z J Psychiatry. 2015 May;49(5):462-70. doi: 10.1177/0004867414561527. Epub 2014 Nov 25.

PMID:
25425742
9.

Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study.

Gründer G, Heinze M, Cordes J, Mühlbauer B, Juckel G, Schulz C, Rüther E, Timm J; NeSSy Study Group.

Lancet Psychiatry. 2016 Aug;3(8):717-29. doi: 10.1016/S2215-0366(16)00085-7. Epub 2016 Jun 2.

PMID:
27265548
10.

Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis.

Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU.

Int J Neuropsychopharmacol. 2013 Jul;16(6):1205-18. doi: 10.1017/S1461145712001277. Epub 2012 Dec 3. Review.

11.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
12.

Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.

Pilla Reddy V, Kozielska M, Suleiman AA, Johnson M, Vermeulen A, Liu J, de Greef R, Groothuis GM, Danhof M, Proost JH.

Schizophr Res. 2013 May;146(1-3):153-61. doi: 10.1016/j.schres.2013.02.010. Epub 2013 Mar 6.

13.

Impaired Social and Role Function in Ultra-High Risk for Psychosis and First-Episode Schizophrenia: Its Relations with Negative Symptoms.

Lee SJ, Kim KR, Lee SY, An SK.

Psychiatry Investig. 2017 Mar;14(2):186-192. doi: 10.4306/pi.2017.14.2.186. Epub 2017 Mar 6.

14.

Cognitive deficits in clinical and familial high risk groups for psychosis are common as in first episode schizophrenia.

Üçok A, Direk N, Koyuncu A, Keskin-Ergen Y, Yüksel Ç, Güler J, Karadayı G, Akturan E, Devrim-Üçok M.

Schizophr Res. 2013 Dec;151(1-3):265-9. doi: 10.1016/j.schres.2013.10.030. Epub 2013 Nov 18.

PMID:
24262680
15.

Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia.

Marchiaro L, Rocca P, LeNoci F, Longo P, Montemagni C, Rigazzi C, Bogetto F.

J Clin Psychiatry. 2005 Nov;66(11):1423-31.

PMID:
16420080
16.

Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis.

Velthorst E, Nieman DH, Becker HE, van de Fliert R, Dingemans PM, Klaassen R, de Haan L, van Amelsvoort T, Linszen DH.

Schizophr Res. 2009 Apr;109(1-3):60-5. doi: 10.1016/j.schres.2009.02.002. Epub 2009 Mar 9.

PMID:
19272756
17.

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.

Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA.

Am J Psychiatry. 2008 Nov;165(11):1420-31. doi: 10.1176/appi.ajp.2008.08050756. Epub 2008 Sep 15. Erratum in: Am J Psychiatry. 2008 Nov;165(11):1495.

PMID:
18794207
18.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
19.

Quetiapine : A Review of its Use in Schizophrenia.

Gunasekara NS, Spencer CM.

CNS Drugs. 1998 Apr;9(4):325-40. doi: 10.2165/00023210-199809040-00007.

PMID:
27521016
20.

Basic symptoms and psychotic symptoms: their relationships in the at risk mental states, first episode and multi-episode schizophrenia.

Comparelli A, De Carolis A, Emili E, Rigucci S, Falcone I, Corigliano V, Curto M, Trovini G, Dehning J, Kotzalidis GD, Girardi P.

Compr Psychiatry. 2014 May;55(4):785-91. doi: 10.1016/j.comppsych.2014.01.006. Epub 2014 Jan 17.

PMID:
24556516

Supplemental Content

Support Center